These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32163529)

  • 1. Mirogabalin besylate in the treatment of neuropathic pain.
    Burgess J; Javed S; Frank B; Malik RA; Alam U
    Drugs Today (Barc); 2020 Feb; 56(2):135-149. PubMed ID: 32163529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirogabalin: First Global Approval.
    Deeks ED
    Drugs; 2019 Mar; 79(4):463-468. PubMed ID: 30778848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.
    Tetsunaga T; Tetsunaga T; Nishida K; Misawa H; Takigawa T; Yamane K; Tsuji H; Takei Y; Ozaki T
    J Orthop Surg Res; 2020 May; 15(1):191. PubMed ID: 32456647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige
    Kitano Y; Kai K; Yamamura N; Yoshiba S; Kuroha M
    Nihon Yakurigaku Zasshi; 2019; 154(6):352-361. PubMed ID: 31787689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the
    Domon Y; Arakawa N; Inoue T; Matsuda F; Takahashi M; Yamamura N; Kai K; Kitano Y
    J Pharmacol Exp Ther; 2018 Jun; 365(3):573-582. PubMed ID: 29563324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
    Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
    J Diabetes Investig; 2020 May; 11(3):693-698. PubMed ID: 31722446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of a new voltage-gated Ca
    Kato J; Inoue T; Yokoyama M; Kuroha M
    Expert Opin Pharmacother; 2021 Dec; 22(17):2311-2322. PubMed ID: 34431423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
    Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
    Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids.
    Tang H; Lu J; Duan Y; Li D
    Mediators Inflamm; 2023; 2023():4893436. PubMed ID: 37152369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
    Hutmacher MM; Frame B; Miller R; Truitt K; Merante D
    J Clin Pharmacol; 2016 Jan; 56(1):67-77. PubMed ID: 26073181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy.
    Hong LM; Liu JM; Lin L; Huang CC; Chen R; Lin WW
    Eur J Pharm Sci; 2024 Jun; 197():106777. PubMed ID: 38649099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic effects of mirogabalin, a novel ligand for α
    Saeki K; Yasuda SI; Kato M; Kano M; Domon Y; Arakawa N; Kitano Y
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Jun; 392(6):723-728. PubMed ID: 30770951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit.
    Zajączkowska R; Mika J; Leppert W; Kocot-Kępska M; Malec-Milewska M; Wordliczek J
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33572689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic effects of the novel α
    Murasawa H; Kobayashi H; Saeki K; Kitano Y
    Psychopharmacology (Berl); 2020 Jan; 237(1):189-197. PubMed ID: 31515584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirogabalin activates the descending noradrenergic system by binding to the α
    Oyama M; Watanabe S; Iwai T; Tanabe M
    J Pharmacol Sci; 2021 May; 146(1):33-39. PubMed ID: 33858653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of mirogabalin, a novel ligand for the α₂δ subunit of voltage-gated calcium channels, on N-type calcium channel currents of rat dorsal root ganglion culture neurons.
    Kitano Y; Wakimoto S; Tamura S; Kubota K; Domon Y; Arakawa N; Saito M; Sava B; Buisson B
    Pharmazie; 2019 Mar; 74(3):147-149. PubMed ID: 30961679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence.
    Chen EY; Beutler SS; Kaye AD; Edinoff AN; Khademi SH; Stoltz AE; Rueb NR; Cornett EM; Suh WJ
    Anesth Pain Med; 2021 Dec; 11(6):e121402. PubMed ID: 35291398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analgesic effects of the novel α₂δ ligand mirogabalin in a rat model of spinal cord injury.
    Domon Y; Kitano Y; Makino M
    Pharmazie; 2018 Nov; 73(11):659-661. PubMed ID: 30396385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirogabalin: could it be the next generation gabapentin or pregabalin?
    Kim JY; Abdi S; Huh B; Kim KH
    Korean J Pain; 2021 Jan; 34(1):4-18. PubMed ID: 33380563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study.
    Merante D; Rosenstock J; Sharma U; Feins K; Hsu C; Vinik A;
    Pain Med; 2017 Nov; 18(11):2198-2207. PubMed ID: 28371941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.